Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

January 19, 2024

https://www.globenewswire.com/news-release/2023/12/21/2799956/0/en/Immutep-Receives-Constructive-Regulatory-Feedback-on-TACTI-004-Registrational-Trial-in-Metastatic-Non-Small-Cell-Lung-Cancer.html

Media Release

SYDNEY, AUSTRALIA, Dec. 21, 2023 (GLOBE NEWSWIRE) — Immutep Limited (ASX:IMM; NASDAQ:IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces constructive feedback has been received from the Paul-Ehrlich-Institut (“PEI”), a German regulatory authority and part of the Committee for Medicinal Products for Human Use (CHMP), regarding the planned TACTI-004 Phase III trial of eftilagimod alpha (“efti”) for first line treatment of metastatic non-small cell lung cancer (NSCLC).

Read more at globenewswire.com

Related news for (IMMP)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.